2025SAFEAnthracycline cardiotoxicityIn 262 women with non-metastatic breast cancer receiving anthracycline-based chemotherapy, ramipril, bisoprolol or both for 12 months reduced subclinical cardiac damage at 24 months compared with placebo.
2023STOP-CAStatin cardioprotectionIn 300 patients with lymphoma scheduled for anthracycline-based chemotherapy, atorvastatin 40 mg daily for 12 months reduced the proportion of patients with an ejection-fraction decline of at least 10 % to below 55 % compared with placebo.
2022POISE-3Antifibrinolytic therapyIn 9,535 patients undergoing non-cardiac surgery at risk of bleeding and cardiovascular events, intravenous tranexamic acid reduced life-threatening, major or critical-organ bleeding at 30 days, but non-inferiority for the cardiovascular safety composite was not established compared with placebo.
2018MANAGEAntithrombotic therapyIn 1,754 patients with myocardial injury after non-cardiac surgery, dabigatran 110 mg twice daily reduced major vascular complications without a significant increase in major bleeding compared with placebo.
2017MANTICORE 101-BreastHER2 cardiotoxicityIn 94 patients with HER2-positive early breast cancer starting adjuvant trastuzumab, perindopril or bisoprolol did not prevent trastuzumab-mediated left ventricular remodelling, although both attenuated the fall in ejection fraction, compared with placebo.
2016PRADAAnthracycline cardiotoxicityIn 130 women with early breast cancer receiving adjuvant anthracycline-based chemotherapy, concomitant candesartan attenuated the early decline in left ventricular ejection fraction on cardiac MRI, whereas metoprolol did not, compared with placebo.
2014POISE-2Aspirin and clonidineIn 10,010 patients at risk of vascular complications undergoing non-cardiac surgery, neither low-dose aspirin nor clonidine started just before surgery reduced death or non-fatal myocardial infarction at 30 days; aspirin increased major bleeding and clonidine increased hypotension, compared with placebo.
2013OVERCOMENeurohormonal prophylaxisIn 90 patients with malignant haemopathies undergoing intensive chemotherapy or autologous stem-cell transplantation, enalapril plus carvedilol started before chemotherapy preserved left ventricular ejection fraction and reduced death or heart failure at 6 months compared with no cardioprotective treatment.
2008POISEBeta-blockadeIn 8,351 patients with or at risk of atherosclerotic disease undergoing non-cardiac surgery, extended-release metoprolol started hours before surgery reduced cardiovascular death, non-fatal myocardial infarction or non-fatal cardiac arrest at 30 days but increased death and stroke compared with placebo.
2004CARPPreoperative revascularisationIn 510 patients with stable coronary artery disease scheduled for elective major vascular surgery, prophylactic coronary revascularisation before surgery did not reduce long-term all-cause mortality or postoperative myocardial infarction compared with no preoperative revascularisation.